PL3532457T3 - Postacie krystaliczne hydroksynorketaminy - Google Patents

Postacie krystaliczne hydroksynorketaminy

Info

Publication number
PL3532457T3
PL3532457T3 PL18758671T PL18758671T PL3532457T3 PL 3532457 T3 PL3532457 T3 PL 3532457T3 PL 18758671 T PL18758671 T PL 18758671T PL 18758671 T PL18758671 T PL 18758671T PL 3532457 T3 PL3532457 T3 PL 3532457T3
Authority
PL
Poland
Prior art keywords
hydroxynorketamine
crystalline forms
crystalline
forms
Prior art date
Application number
PL18758671T
Other languages
English (en)
Inventor
David Pearson
Lorraine SHARP
Alan Armstrong
Richard MYERSON
Jonathan Hull
Paul Blaney
Peter RANDS
Marie LAYZELL
Zelah JOEL
Original Assignee
Small Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1712304.3A external-priority patent/GB201712304D0/en
Priority claimed from GBGB1715010.3A external-priority patent/GB201715010D0/en
Priority claimed from GBGB1715500.3A external-priority patent/GB201715500D0/en
Application filed by Small Pharma Ltd filed Critical Small Pharma Ltd
Publication of PL3532457T3 publication Critical patent/PL3532457T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/44—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton bound to carbon atoms of the same ring or condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D201/00—Preparation, separation, purification or stabilisation of unsubstituted lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL18758671T 2017-07-31 2018-07-31 Postacie krystaliczne hydroksynorketaminy PL3532457T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1712304.3A GB201712304D0 (en) 2017-07-31 2017-07-31 Synthetic methods
GBGB1715010.3A GB201715010D0 (en) 2017-09-18 2017-09-18 Crystalline forms
GBGB1715500.3A GB201715500D0 (en) 2017-09-25 2017-09-25 Crystal forms of therapeutic compounds and dosage forms thereof
EP18758671.4A EP3532457B1 (en) 2017-07-31 2018-07-31 Crystalline forms of hydroxynorketamine
PCT/GB2018/052193 WO2019025792A1 (en) 2017-07-31 2018-07-31 CRYSTALLINE FORMS OF HYDROXYNORKETAMINE

Publications (1)

Publication Number Publication Date
PL3532457T3 true PL3532457T3 (pl) 2020-10-19

Family

ID=63294366

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18758671T PL3532457T3 (pl) 2017-07-31 2018-07-31 Postacie krystaliczne hydroksynorketaminy

Country Status (9)

Country Link
US (2) US11377416B2 (pl)
EP (1) EP3532457B1 (pl)
JP (1) JP2020529445A (pl)
CN (1) CN111201217A (pl)
AU (1) AU2018311307B9 (pl)
CA (1) CA3071491A1 (pl)
ES (1) ES2797381T3 (pl)
PL (1) PL3532457T3 (pl)
WO (1) WO2019025792A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110343050B (zh) 2018-04-04 2021-09-24 上海键合医药科技有限公司 芳香类化合物及其制备方法和用途
WO2021101867A1 (en) * 2019-11-18 2021-05-27 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Salts of (2r, 6r)-hydroxynorketamine, their crystal forms, and methods of making the same
WO2022047256A1 (en) * 2020-08-27 2022-03-03 University Of Maryland, Baltimore Hydroxynorketamine compounds and methods of use thereof
CN112521357B (zh) * 2020-08-31 2021-10-08 深圳瑞健生物科技有限公司 一种长效低成瘾性hnk衍生物及其制备方法
US12396981B2 (en) 2023-03-09 2025-08-26 William Shulman Methods of using DMT

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817699A (en) 1997-05-30 1998-10-06 Flores; John A. Process for the preparation of ketamine ointment
KR100467669B1 (ko) * 2002-08-21 2005-01-24 씨제이 주식회사 암로디핀의 유기산염
CN104395283A (zh) 2011-10-14 2015-03-04 美国政府健康及人类服务部 (2r,6r)-羟基去甲氯胺酮、(s)-脱氢去甲氯胺酮以及(r,s)-氯胺酮的其他立体异构脱氢和羟基化代谢物在治疗忧郁症和神经性疼痛中的应用
WO2014020155A1 (en) 2012-08-02 2014-02-06 Clinpharm Reform Gmbh Oral transmucosal adminstration forms of s-ketamine
EP2948135B1 (en) 2013-01-25 2019-01-02 Case Western Reserve University Compositions and methods for the treatment of pervasive development disorders
CA2936809A1 (en) 2014-01-14 2015-07-23 Children's Hospital Medical Center Compositions comprising ketamine for treating an autism spectrum disorder
RU2771275C2 (ru) 2014-11-04 2022-04-29 Аморса Терапьютикс, Инк. Нейро-аттенуирующие кетаминовые и норкетаминовые соединения, их производные и способы их получения
JO3456B1 (ar) * 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
WO2016186968A1 (en) 2015-05-15 2016-11-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating motor disorders
WO2017087691A1 (en) 2015-11-17 2017-05-26 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
US11111210B2 (en) 2015-11-18 2021-09-07 Spirify Pharma Inc. Phenyl cyclohexanone derivatives and methods of making and using them
WO2017180589A1 (en) 2016-04-11 2017-10-19 Auspex Pharmaceuticals, Inc. Deuterated ketamine derivatives
US20190380978A1 (en) 2016-06-03 2019-12-19 Small Pharma Ltd Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof
CN110035997A (zh) 2016-09-16 2019-07-19 生物制药沃克斯有限公司 羟基去甲氯胺酮前药
US20190240184A1 (en) 2016-10-27 2019-08-08 National University Corporation Chiba University Pharmaceutical applications for (s)-norketamine and salts thereof
CA3045148A1 (en) 2016-11-30 2018-06-07 Philip E. Wolfson Ketamine for the treatment of menstrually related symptoms
US20210315840A1 (en) 2017-09-25 2021-10-14 Small Pharma Ltd Solid oral dosage forms of ketamine derivatives

Also Published As

Publication number Publication date
AU2018311307B9 (en) 2021-09-09
CA3071491A1 (en) 2019-02-07
US20200157040A1 (en) 2020-05-21
JP2020529445A (ja) 2020-10-08
AU2018311307A1 (en) 2020-02-13
US11377416B2 (en) 2022-07-05
WO2019025792A1 (en) 2019-02-07
US20220306569A1 (en) 2022-09-29
EP3532457B1 (en) 2020-03-18
AU2018311307B2 (en) 2021-08-12
EP3532457A1 (en) 2019-09-04
ES2797381T3 (es) 2020-12-02
CN111201217A (zh) 2020-05-26

Similar Documents

Publication Publication Date Title
IL273730A (en) crystalline forms
SG10201913200XA (en) Crystalline form of lorlatinib free base
ZA201906464B (en) Crystalline forms of (s)-afoxolaner
PL3577125T3 (pl) Postacie krystaliczne alafenamidu tenofowiru
IL246385B (en) Crystalline forms of efitinib di-malate
SI3380554T1 (sl) Kristalne oblike per-kloro-gama-ciklodekstrinov
PL3113773T3 (pl) Krystaliczne postaci grapiprantu
SI3529236T1 (sl) Kristalinične oblike eravaciklina
SG10202101979TA (en) Crystalline forms of c21h22ci2n4o2
IL270961A (en) Crystalline form of N-butyldeoxygalactonogirimycin
IL269073A (en) Crystalline forms of obeticholic acid
IL265445A (en) crystalline forms
IL253479A0 (en) Crystalline forms of efinconazole
GB201518589D0 (en) Crystalline form of tetraacetylethylenediamine
IL270937A (en) Crystalline forms of saltalicib
ZA201902553B (en) Crystalline forms
GB201715010D0 (en) Crystalline forms
HK40025092A (en) Crystalline form of n-butyldeoxygalactonojirimycin
GB201721386D0 (en) Chrondogy of time-wave
HK40014545A (en) Crystalline forms of (s)-afoxolaner
CA3308777A1 (en) Crystalline forms of c21h22ci2n4o2
GB201721728D0 (en) Compounds